101 related articles for article (PubMed ID: 8035336)
1. Diarrhea associated with intestinal inflammation increases the potency of mu and delta opioids on the inhibition of gastrointestinal transit in mice.
Pol O; Ferrer I; Puig MM
J Pharmacol Exp Ther; 1994 Jul; 270(1):386-91. PubMed ID: 8035336
[TBL] [Abstract][Full Text] [Related]
2. Antidiarrheal properties of supraspinal mu and delta and peripheral mu, delta and kappa opioid receptors: inhibition of diarrhea without constipation.
Shook JE; Lemcke PK; Gehrig CA; Hruby VJ; Burks TF
J Pharmacol Exp Ther; 1989 Apr; 249(1):83-90. PubMed ID: 2540324
[TBL] [Abstract][Full Text] [Related]
3. Antiexudative effects of opioids and expression of kappa- and delta-opioid receptors during intestinal inflammation in mice: involvement of nitric oxide.
Jiménez N; Puig MM; Pol O
J Pharmacol Exp Ther; 2006 Jan; 316(1):261-70. PubMed ID: 16183704
[TBL] [Abstract][Full Text] [Related]
4. Intestinal inflammation enhances the inhibitory effects of opioids on intestinal permeability in mice.
Valle L; Pol O; Puig MM
J Pharmacol Exp Ther; 2001 Feb; 296(2):378-87. PubMed ID: 11160621
[TBL] [Abstract][Full Text] [Related]
5. Effects of mu, kappa or delta opioids administered by pellet or pump on oral Salmonella infection and gastrointestinal transit.
Feng P; Rahim RT; Cowan A; Liu-Chen LY; Peng X; Gaughan J; Meissler JJ; Adler MW; Eisenstein TK
Eur J Pharmacol; 2006 Mar; 534(1-3):250-7. PubMed ID: 16513108
[TBL] [Abstract][Full Text] [Related]
6. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
Baker AK; Meert TF
J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687
[TBL] [Abstract][Full Text] [Related]
7. Reversal of tolerance to the antitransit effects of morphine during acute intestinal inflammation in mice.
Pol O; Puig MM
Br J Pharmacol; 1997 Nov; 122(6):1216-22. PubMed ID: 9401789
[TBL] [Abstract][Full Text] [Related]
8. Peripheral effects of opioids in a model of chronic intestinal inflammation in mice.
Puig MM; Pol O
J Pharmacol Exp Ther; 1998 Dec; 287(3):1068-75. PubMed ID: 9864294
[TBL] [Abstract][Full Text] [Related]
9. Delta opioid-like discriminative stimulus effects of mu opioids in pigeons discriminating the delta opioid BW373U86 from saline.
Picker MJ; Cook CD
Behav Pharmacol; 1998 Jul; 9(4):319-28. PubMed ID: 10065920
[TBL] [Abstract][Full Text] [Related]
10. Involvement of mu-opioid receptors in antinociception and inhibition of gastrointestinal transit induced by 7-hydroxymitragynine, isolated from Thai herbal medicine Mitragyna speciosa.
Matsumoto K; Hatori Y; Murayama T; Tashima K; Wongseripipatana S; Misawa K; Kitajima M; Takayama H; Horie S
Eur J Pharmacol; 2006 Nov; 549(1-3):63-70. PubMed ID: 16978601
[TBL] [Abstract][Full Text] [Related]
11. Opioids binding mu and delta receptors exhibit diverse efficacy in the activation of Gi2 and G(x/z) transducer proteins in mouse periaqueductal gray matter.
Garzón J; García-España A; Sánchez-Blázquez P
J Pharmacol Exp Ther; 1997 Apr; 281(1):549-57. PubMed ID: 9103543
[TBL] [Abstract][Full Text] [Related]
12. Delta opioid receptor enhancement of mu opioid receptor-induced antinociception in spinal cord.
He L; Lee NM
J Pharmacol Exp Ther; 1998 Jun; 285(3):1181-6. PubMed ID: 9618421
[TBL] [Abstract][Full Text] [Related]
13. Chronic muscle pain induced by repeated acid Injection is reversed by spinally administered mu- and delta-, but not kappa-, opioid receptor agonists.
Sluka KA; Rohlwing JJ; Bussey RA; Eikenberry SA; Wilken JM
J Pharmacol Exp Ther; 2002 Sep; 302(3):1146-50. PubMed ID: 12183674
[TBL] [Abstract][Full Text] [Related]
14. Chronic agonist treatment converts antagonists into inverse agonists at delta-opioid receptors.
Liu JG; Prather PL
J Pharmacol Exp Ther; 2002 Sep; 302(3):1070-9. PubMed ID: 12183665
[TBL] [Abstract][Full Text] [Related]
15. Effects of opioid agonists selective for mu, kappa and delta opioid receptors on schedule-controlled responding in rhesus monkeys: antagonism by quadazocine.
Negus SS; Burke TF; Medzihradsky F; Woods JH
J Pharmacol Exp Ther; 1993 Nov; 267(2):896-903. PubMed ID: 8246165
[TBL] [Abstract][Full Text] [Related]
16. Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification.
Cichewicz DL; Martin ZL; Smith FL; Welch SP
J Pharmacol Exp Ther; 1999 May; 289(2):859-67. PubMed ID: 10215664
[TBL] [Abstract][Full Text] [Related]
17. SNF9007: a novel analgesic that acts simultaneously at delta 1, delta 2 and mu opioid receptors.
Williams CL; Rosenfeld GC; Dafny N; Fang SN; Hruby VJ; Bowden G; Cullinan CA; Burks TF
J Pharmacol Exp Ther; 1994 May; 269(2):750-5. PubMed ID: 8182541
[TBL] [Abstract][Full Text] [Related]
18. Interactions among mu- and delta-opioid receptors, especially putative delta1- and delta2-opioid receptors, promote dopamine release in the nucleus accumbens.
Hirose N; Murakawa K; Takada K; Oi Y; Suzuki T; Nagase H; Cools AR; Koshikawa N
Neuroscience; 2005; 135(1):213-25. PubMed ID: 16111831
[TBL] [Abstract][Full Text] [Related]
19. Antisense oligodeoxynucleotides to opioid mu and delta receptors reduced morphine dependence in mice: role of delta-2 opioid receptors.
Sánchez-Blázquez P; García-Espãna A; Garzón J
J Pharmacol Exp Ther; 1997 Mar; 280(3):1423-31. PubMed ID: 9067332
[TBL] [Abstract][Full Text] [Related]
20. Functional interaction among opioid receptor types: up-regulation of mu- and delta-opioid receptor functions after repeated stimulation of kappa-opioid receptors.
Khotib J; Narita M; Suzuki M; Yajima Y; Suzuki T
Neuropharmacology; 2004 Mar; 46(4):531-40. PubMed ID: 14975677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
